Our Technology Platform
We partner with researchers, guide experimental design, execute high quality processing of complex and valuable biological samples and provide extensive bioinformatics analyses with the aim of making genomics research accessible to our partners and collaborators within the scientific community.
The priority of the platforms is to develop innovative means to automate the sequencing process, develop cost-effective measures that will make such research financially viable, and utilize leading edge computing tools to collect, mine, analyze and disperse data collected at this and other genome facilities. To accomplish this, the platform fully exploits the most recent technological advances in genomics, proteomics, and high performance computing, within a state-of-the-art facility designed to generate and extract information from complex samples and valuable sample collections, for the benefit and use of the wider scientific community.
Learn more about our platforms and services, and if you are interested in partnering with the GSC on your research project, please fill out a contact form or speak with one of our Platform Leaders directly.
Our Scientific Research
The thirteen faculty members at the GSC have a diverse range of expertise in genomics, bioinformatics, proteomics, epigenomics, immunogenetics and cancer biology. Together, we broadly apply our expertise to advance our knowledge of cancer and other diseases, to improve human health through disease prevention, to develop diagnostic and therapeutic approaches and to realize the social and economic benefits of genomics research.
The GSC is CAP, DAP and ISO certified, allowing us to perform clinical sequencing to detect cancer susceptibility mutations through capture panels and whole genome sequencing. Cancer research and clinical programs include:
Support and Funding
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.